CTI Science has completed all pre-clinical work on OSR I (now known as NBMI) and submitted the application to the Swedish Medicinal Products Agency (MPA) to conduct the Phase I clinical study. The plan is to have this first step, in bringing back the product, completed by the end of summer 2014.
After the Phase I study, they will conduct a Phase II efficacy study on mercury toxic humans, and they are currently engaged in planning for that study.
In November 2013, CTI Science was awarded $75,000 by the Swedish research funding agency, Vinnova, to conduct efficacy studies using NBMI to treat a large disease. In the Fall of 2013 CTI Science raised $1 million dollars and need to raise $500,000 more to finish the study.
If you are interested in developing up-dates for OSR I (NBMI), you can follow them at www.ctiscience.com or stay tuned to our blogs and email newsletters.
Rev. Dr. Stephen A. Lawrence
Print